See more : Nepra Foods Inc. (NPRA.CN) Income Statement Analysis – Financial Results
Complete financial analysis of OXYGENTA PHARMACEUTICAL LIMITE (OXYGENTAPH.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OXYGENTA PHARMACEUTICAL LIMITE, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
You may be interested
- Prime Focus Limited (PFOCUS.NS) Income Statement Analysis – Financial Results
- SentinelOne, Inc. (S&J.BK) Income Statement Analysis – Financial Results
- Elior Group SA (ELROF) Income Statement Analysis – Financial Results
- Guangdong Orient Zirconic Ind Sci & Tech Co.,Ltd (002167.SZ) Income Statement Analysis – Financial Results
- MetalNRG plc (MNRG.L) Income Statement Analysis – Financial Results
Oxygenta Pharmaceutical Ltd. (OXYGENTAPH.BO)
About Oxygenta Pharmaceutical Ltd.
Oxygenta Pharmaceutical Ltd. engages in the development and manufacture of bulk drugs. It offers anti-ulcerative and anti-bacterial drugs. The company was founded on November 27, 1990 and is headquartered in Hyderabad, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 396.42M | 309.87M | 605.25M | 520.27M | 137.16M | 205.08M | 128.70M | 81.54M | 124.27M |
| Cost of Revenue | 496.21M | 383.91M | 587.43M | 477.05M | 212.32M | 218.73M | 166.51M | 124.46M | 153.89M |
| Gross Profit | -99.79M | -74.03M | 17.82M | 43.22M | -75.15M | -13.65M | -37.81M | -42.91M | -29.62M |
| Gross Profit Ratio | -25.17% | -23.89% | 2.94% | 8.31% | -54.79% | -6.66% | -29.38% | -52.63% | -23.84% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 135.00K |
| General & Administrative | 21.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 21.38M | 9.65M | 17.03M | 13.73M | 12.80M | 15.89M | 9.16M | 10.89M | 17.01M |
| Other Expenses | 2.40M | -7.90M | -1.82M | -2.89M | -627.28K | -503.83K | -1.79M | -3.13M | -3.13M |
| Operating Expenses | 23.78M | 17.54M | 18.85M | 16.63M | 13.42M | 16.39M | 10.95M | 14.02M | 20.27M |
| Cost & Expenses | 519.77M | 401.45M | 606.28M | 493.67M | 225.74M | 235.12M | 177.46M | 138.48M | 174.16M |
| Interest Income | 178.00K | 50.34K | 44.90K | 225.29K | 236.85K | 129.75K | 178.97K | 77.65K | 0.00 |
| Interest Expense | 15.94M | 14.88M | 9.25M | 17.83M | 10.94M | 7.46M | 9.03M | 5.98M | 5.12M |
| Depreciation & Amortization | 26.61M | 20.52M | 15.91M | 11.96M | 9.99M | 10.19M | 9.40M | 9.01M | 8.24M |
| EBITDA | -96.17M | -78.33M | 20.27M | 61.23M | -38.49M | -17.28M | -26.36M | -47.92M | -41.66M |
| EBITDA Ratio | -24.26% | -22.93% | 2.46% | 7.41% | -57.30% | -9.69% | -30.59% | -58.77% | -33.52% |
| Operating Income | -123.57M | -91.58M | -1.03M | 26.60M | -88.58M | -30.05M | -48.76M | -56.93M | -49.90M |
| Operating Income Ratio | -31.17% | -29.55% | -0.17% | 5.11% | -64.58% | -14.65% | -37.89% | -69.82% | -40.15% |
| Total Other Income/Expenses | -15.15M | -22.15M | -3.86M | 4.84M | 29.16M | -4.88M | 3.97M | -306.77K | -5.12M |
| Income Before Tax | -138.72M | -113.73M | -4.89M | 31.44M | -59.41M | -34.93M | -44.80M | -57.24M | -55.01M |
| Income Before Tax Ratio | -34.99% | -36.70% | -0.81% | 6.04% | -43.31% | -17.03% | -34.81% | -70.19% | -44.27% |
| Income Tax Expense | -103.92M | 1.98M | 1.21M | 2.14M | -1.53M | -2.39M | 484.12K | 851.09K | -15.84K |
| Net Income | -34.79M | -115.71M | -6.10M | 29.30M | -57.88M | -32.54M | -45.28M | -58.09M | -55.00M |
| Net Income Ratio | -8.78% | -37.34% | -1.01% | 5.63% | -42.20% | -15.87% | -35.18% | -71.24% | -44.26% |
| EPS | -1.09 | -8.15 | -0.43 | 2.87 | -5.67 | -3.19 | -4.44 | -5.69 | -5.39 |
| EPS Diluted | -1.09 | -8.15 | -0.43 | 2.87 | -5.67 | -3.19 | -4.44 | -5.69 | -5.39 |
| Weighted Avg Shares Out | 32.04M | 14.20M | 14.20M | 10.20M | 10.20M | 10.20M | 10.20M | 10.20M | 10.20M |
| Weighted Avg Shares Out (Dil) | 32.04M | 14.20M | 14.20M | 10.20M | 10.20M | 10.20M | 10.20M | 10.20M | 10.20M |
No news found for: OXYGENTAPH.BO
Source: https://incomestatements.info
Category: Stock Reports